NYSE:ZTS - Zoetis Stock Price, Price Target & More

$84.73 +0.16 (+0.19 %)

(As of 04/26/2018 04:00 PM ET)

Previous Close$84.73

Today's Range$84.36 - $85.26

52-Week Range$55.48 - $86.38

Volume2.15 million shs

Average Volume2.70 million shs

Market Capitalization$40.93 billion

P/E Ratio35.30

Dividend Yield0.60%

Beta0.96

About Zoetis (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:ZTS

CUSIP98978V10

Webwww.zoetis.com

Phone973-822-7000

Debt

Debt-to-Equity Ratio2.77%

Current Ratio3.85%

Quick Ratio2.55%

Price-To-Earnings

Trailing P/E Ratio35.30

Forward P/E Ratio27.87

P/E Growth1.87

Sales & Book Value

Annual Sales$5.31 billion

Price / Sales7.75

Cash Flow$2.9420 per share

Price / Cash28.80

Book Value$3.67 per share

Price / Book23.09

Profitability

EPS (Most Recent Fiscal Year)$2.40

Net Income$864 million

Net Margins16.28%

Return on Equity65.96%

Return on Assets14.22%

Miscellaneous

Employees9,200

Outstanding Shares485,250,000

How to Become a New Pot Stock Millionaire

Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Wednesday, February 14th. Shareholders of record on Friday, April 20th will be given a dividend of $0.126 per share on Friday, June 1st. This represents a $0.50 annualized dividend and a dividend yield of 0.59%. The ex-dividend date is Thursday, April 19th. View Zoetis' Dividend History.

How were Zoetis' earnings last quarter?

Zoetis (NYSE:ZTS) issued its earnings results on Thursday, February, 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.66 by $0.03. The company earned $1.46 billion during the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.47 earnings per share. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY18 earnings guidance on Thursday, February, 15th. The company provided earnings per share guidance of $2.96-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.98. The company issued revenue guidance of $5.675-5.8 billion, compared to the consensus revenue estimate of $5.62 billion.

What price target have analysts set for ZTS?

18 brokerages have issued 1 year target prices for Zoetis' shares. Their predictions range from $62.00 to $98.00. On average, they expect Zoetis' stock price to reach $82.0588 in the next twelve months. View Analyst Ratings for Zoetis.

What are Wall Street analysts saying about Zoetis stock?

Here are some recent quotes from research analysts about Zoetis stock:

1. According to Zacks Investment Research, "Zoetis faces stiff competition from other animal health medicines and vaccines companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly), Bayer Animal Health (the animal health division of Bayer) and Boehringer Ingelheim Animal Health (the animal health division of Boehringer Ingelheim). Disease outbreak among animals is a material cause of concern for Zoetis’ livestock products.In addition, companion animal health products are often directly prescribed and dispensed by veterinarians. The swine business is being impacted by competition for Fostera. These competitive pressures could adversely affect the company’s business and operating results. However, shares of the company have outperformed the industry in the last six months." (1/13/2018)
2. Cantor Fitzgerald analysts commented, "IDEXX Laboratories this morning provided strong 2018 organic growth forecasts of 9% to 11% driven by the strong growth in its Companion Animal Diagnostics segment." (10/31/2017)

Who are some of Zoetis' key competitors?

Some companies that are related to Zoetis include Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX) and Takeda Pharmaceutical (TKPYY).

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:

Mr. Juan Ramón Alaix, CEO & Director (Age 67)
Mr. Glenn C. David, Exec. VP, CFO & Principal Accounting Officer (Age 46)
Mr. Clinton A. Lewis Jr., Exec. VP & Pres of International Operations (Age 51)
Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 57)
Ms. Kristin C. Peck, Exec. VP and Group Pres, U.S. Operations, Bus. Devel. & Strategy (Age 47)

Has Zoetis been receiving favorable news coverage?

News stories about ZTS stock have trended positive recently, according to Accern. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a daily sentiment score of 0.41 on Accern's scale. They also assigned news stories about the company an impact score of 45.77 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $84.73.

How big of a company is Zoetis?

Zoetis has a market capitalization of $40.93 billion and generates $5.31 billion in revenue each year. The company earns $864 million in net income (profit) each year or $2.40 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]

MarketBeat Community Rating for Zoetis (ZTS)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		515 (Vote Outperform)
Underperform Votes:		307 (Vote Underperform)
Total Votes:		822

MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Zoetis (NYSE:ZTS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Zoetis in the last 12 months. Their average twelve-month price target is $82.0588, suggesting that the stock has a possible downside of 3.15%. The high price target for ZTS is $98.00 and the low price target for ZTS is $62.00. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.61	2.67	2.67	2.63
Ratings Breakdown:	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$82.0588	$79.5294	$73.1765	$65.4375
Price Target Upside:	3.15% downside	5.99% downside	4.49% downside	0.70% upside

Zoetis (NYSE:ZTS) Consensus Price Target History

Price Target History for Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/25/2018	Craig Hallum	Reiterated Rating	Buy	$87.00 -> $94.00	Low
4/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$90.00	Medium
4/19/2018	Hilliard Lyons	Downgrade	Neutral		Low
4/19/2018	Citigroup	Reiterated Rating	Buy -> Buy	$85.00 -> $98.00	Low
4/13/2018	Jefferies Group	Reiterated Rating	Buy	$96.00	Low
4/5/2018	Credit Suisse Group	Boost Price Target	Outperform -> Outperform	$83.00 -> $89.00	Low
3/19/2018	Morgan Stanley	Downgrade	Overweight -> Equal Weight	$70.00	Low
2/17/2018	Barclays	Set Price Target	Hold	$77.00	Medium
2/16/2018	Deutsche Bank	Boost Price Target	Hold -> Hold	$76.00 -> $78.00	Low
2/16/2018	Piper Jaffray	Set Price Target	Buy	$88.00	Low
2/16/2018	Stifel Nicolaus	Reiterated Rating	Buy -> Buy	$84.00 -> $86.00	Medium
2/16/2018	Bank of America	Boost Price Target	Buy	$80.00 -> $87.00	Medium
2/15/2018	BMO Capital Markets	Set Price Target	Hold	$78.00	Medium
2/15/2018	Cowen	Set Price Target	Buy	$85.00	Medium
11/24/2017	UBS	Reiterated Rating	Buy -> Neutral		N/A
8/7/2017	Goldman Sachs	Reiterated Rating	Neutral -> Neutral	$62.00	Low
5/30/2017	Argus	Reiterated Rating	Buy	$60.00 -> $69.00	Low
5/26/2017	CL King	Initiated Coverage	Buy -> Buy	$71.00	Low
2/16/2017	Guggenheim	Boost Price Target	Buy	$60.00 -> $65.00	N/A
2/16/2017	Off Wall Street	Reiterated Rating	Strong Sell	$35.00	N/A
11/3/2016	JPMorgan Chase	Reiterated Rating	Hold	$53.00	N/A

(Data available from 4/26/2016 forward)

Zoetis (NYSE:ZTS) Earnings History and Estimates Chart

Earnings by Quarter for Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS) Earnings Estimates

2018 EPS Consensus Estimate: $3.05

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.70	$0.71	$0.71
Q2 2018	1	$0.72	$0.72	$0.72
Q3 2018	1	$0.79	$0.79	$0.79
Q4 2018	1	$0.83	$0.83	$0.83

Zoetis (NYSE ZTS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		$0.68					N/A
2/15/2018	Q4 2017	$0.66	$0.69	$1.4034 billion	$1.46 billion	View	N/A
11/2/2017	Q3 2017	$0.63	$0.65	$1.3206 billion	$1.3470 billion	View	N/A
8/8/2017	Q2 2017	$0.53	$0.5280	$1.2660 billion	$1.2690 billion	View	Listen
5/4/2017	Q1 2017	$0.48	$0.53	$1.1967 billion	$1.2310 billion	View	Listen
2/16/2017	Q416	$0.45	$0.47	$1.28 billion	$1.30 billion	View	N/A
11/2/2016	Q316	$0.46	$0.52	$1.22 billion	$1.20 billion	View	N/A
8/3/2016	Q216	$0.44	$0.49	$1.17 billion	$1.20 billion	View	N/A
5/4/2016	Q116	$0.41	$0.48	$1.10 billion	$1.20 billion	View	N/A
2/16/2016	Q415	$0.39	$0.43	$1.25 billion	$1.30 billion	View	Listen
11/3/2015	Q315	$0.40	$0.50	$1.18 billion	$1.20 billion	View	N/A
8/4/2015	Q215	$0.38	$0.43	$1.12 billion	$1.20 billion	View	N/A
5/5/2015	Q115	$0.37	$0.41	$1.11 billion	$1.10 billion	View	N/A
2/11/2015	Q414	$0.36	$0.40	$1.27 billion	$1.30 billion	View	N/A
11/4/2014	Q314	$0.37	$0.41	$1.16 billion	$1.20 billion	View	N/A
8/5/2014	Q2 2014	$0.39	$0.38	$1.1640 billion	$1.1580 billion	View	N/A
5/6/2014	Q114	$0.37	$0.38	$1.13 billion	$1.10 billion	View	N/A
2/11/2014	Q413	$0.34	$0.36	$1.21 billion	$1.25 billion	View	N/A
11/5/2013	Q313	$0.34	$0.34	$1.07 billion	$1.10 billion	View	N/A
8/6/2013	Q2 2013	$0.36	$0.36	$1.13 billion	$1.1140 billion	View	N/A
4/30/2013	Q1 2013	$0.27	$0.36	$1.24 billion	$1.09 billion	View	N/A
3/28/2013	Q4 2012	$0.34	$0.07			View	N/A

(Earnings results data provided by Zacks Investment Research)

Zoetis (NYSE:ZTS) Dividend Information

Zoetis pays an annual dividend of $0.50 per share, with a dividend yield of 0.59%. ZTS's next quarterly dividend payment will be made on Friday, June 1. The company has grown its dividend for the last 4 consecutive years and is increasing its dividend by an average of 13.40% each year. Zoetis pays out 20.83% of its earnings out as a dividend.

Next Dividend:	6/1/2018
Annual Dividend:	$0.50
Dividend Yield:	0.59%
Dividend Growth:	13.40% (3 Year Average)
Payout Ratio:	20.83% (Trailing 12 Months of Earnings) 16.45% (Based on This Year's Estimates) 14.58% (Based on Next Year's Estimates)
Track Record:	4 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/14/2018	quarterly	$0.1260	0.68%	4/19/2018	4/20/2018	6/1/2018
12/12/2017	quarterly	$0.1260	0.7%	1/18/2018	1/19/2018	3/1/2018
10/5/2017	quarterly	$0.1050	0.66%	11/8/2017	11/9/2017	12/1/2017
5/12/2017	quarterly	$0.1050	0.7%	6/13/2017	6/15/2017	9/1/2017
2/15/2017	quarterly	$0.1050	0.76%	4/4/2017	4/6/2017	6/1/2017
12/6/2016	quarterly	$0.1050	0.82%	1/18/2017	1/20/2017	3/1/2017
10/7/2016	quarterly	$0.0950	0.73%	11/1/2016	11/3/2016	12/1/2016
5/13/2016	quarterly	$0.0950	0.82%	6/28/2016	6/30/2016	8/30/2016
2/22/2016	quarterly	$0.0950	0.89%	4/5/2016	4/7/2016	6/1/2016
12/17/2015	quarterly	$0.0950	0.81%	1/19/2016	1/21/2016	3/1/2016
10/2/2015	quarterly	$0.0830	0.77%	11/3/2015	11/5/2015	12/1/2015
7/22/2015	quarterly	$0.0830	0.66%	8/11/2015	8/13/2015	9/1/2015
3/2/2015	quarterly	$0.0830	0.7%	4/7/2015	4/9/2015	6/2/2015
12/18/2014	quarterly	$0.0830	0.77%	1/20/2015	1/22/2015	3/3/2015
10/2/2014	quarterly	$0.0720	0.76%	11/3/2014	11/5/2014	12/2/2014
7/31/2014	quarterly	$0.0720	0.88%	8/18/2014	8/20/2014	9/2/2014
3/26/2014	quarterly	$0.0720	0.98%	4/23/2014	4/27/2014	6/2/2014
12/19/2013	quarterly	$0.0720	0.89%	1/28/2014	1/30/2014	3/4/2014
9/12/2013	quarterly	$0.0650	0.84%	10/30/2013	11/1/2013	12/2/2013
6/20/2013	quarterly	$0.0650			8/1/2013	9/2/2013
3/29/2013	special	$0.0650		4/29/2013	5/1/2013	6/6/2013
3/28/2013	quarterly	$0.0650			5/1/2013	6/6/2013

(Data available from 1/1/2013 forward)

Zoetis (NYSE ZTS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.35%
Institutional Ownership Percentage: 92.45%

Insider Trading History for Zoetis (NYSE:ZTS)

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Zoetis (NYSE ZTS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2018	Heidi C Chen	Insider	Sell	7,383	$84.71	$625,413.93	20,162
3/9/2018	Roman Trawicki	Insider	Sell	8,568	$83.10	$712,000.80	11,457
2/23/2018	Roman Trawicki	Insider	Sell	23,885	$82.00	$1,958,570.00
2/21/2018	Roxanne Lagano	EVP	Sell	35,663	$81.02	$2,889,416.26	49,919
2/20/2018	Heidi C Chen	Insider	Sell	37,453	$81.02	$3,034,442.06
5/12/2017	Catherine A Knupp	Insider	Sell	5,785	$60.16	$348,025.60	24,415
11/22/2016	Kristin C Peck	Insider	Sell	10,092	$49.55	$500,058.60	22,768
11/8/2016	Roxanne Lagano	Insider	Sell	9,797	$50.43	$494,062.71	8,063
9/6/2016	Michael B Mccallister	Director	Buy	2,000	$51.34	$102,680.00
9/2/2016	Andrew Fenton	Insider	Sell	13,870	$51.25	$710,837.50	17,719
9/1/2016	Heidi C Chen	Insider	Sell	32,097	$50.98	$1,636,305.06	46,060
5/9/2016	Pershing Square Capital Manage	Director	Sell	16,850,000	$46.55	$784,367,500.00
8/8/2013	Michael Mccallister	Director	Buy	7,000	$31.35	$219,450.00
2/6/2013	Frank A Damelio	Director	Buy	5,000	$26.00	$130,000.00
2/6/2013	Sandra J Beaty	EVP	Buy	2,000	$26.00	$52,000.00

(Data available from 1/1/2013 forward)

Zoetis (NYSE ZTS) News Headlines

Source:

Date	Headline
	BRIEF-Zoetis Inc To Expand Animal Vaccine Research And Manufacturing In Suzhou, China www.reuters.com - April 26 at 9:41 AM
	Zoetis to Expand Animal Vaccine Research and Manufacturing in Suzhou, China finance.yahoo.com - April 26 at 9:41 AM
	Zoetis (ZTS) Earns "Buy" Rating from Craig Hallum www.americanbankingnews.com - April 25 at 11:42 AM
	Zoetis (ZTS) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 25 at 4:10 AM
	Zoetis (ZTS) Given a $90.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - April 24 at 10:28 AM
	Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance finance.yahoo.com - April 24 at 9:41 AM
	Hilliard Lyons Downgrades Zoetis Inc. (ZTS) to Neutral 'Strickly Due to Valuation' www.streetinsider.com - April 21 at 9:34 AM
	Zoetis (ZTS) Given a $60.00 Price Target at Cowen www.americanbankingnews.com - April 19 at 5:18 PM
	Zoetis (ZTS) Downgraded by Hilliard Lyons to "Neutral" www.americanbankingnews.com - April 19 at 10:42 AM
	UPDATE: Zoetis Inc. (ZTS) PT Raised to Street High $98 at Citi www.streetinsider.com - April 19 at 9:57 AM
	Zoetis (ZTS) Earns "Buy" Rating from Citigroup www.americanbankingnews.com - April 19 at 9:04 AM
	Zoetis Inc. (ZTS) Ex-Dividend Date Scheduled for April 19, 2018 www.nasdaq.com - April 18 at 10:00 AM
	Zoetis (ZTS) Given a $70.00 Price Target at Cowen www.americanbankingnews.com - April 17 at 10:55 PM
	Ex-Dividend Reminder: Foot Locker, Zoetis and First Busey www.nasdaq.com - April 17 at 4:25 PM
	Jefferies Group Comments on Zoetis' Q1 2018 Earnings (ZTS) www.americanbankingnews.com - April 16 at 1:12 AM
	Jefferies Group Analysts Give Zoetis (ZTS) a $96.00 Price Target www.americanbankingnews.com - April 13 at 10:13 AM
	Goldman Sachs Reaffirms "Neutral" Rating for Zoetis (ZTS) www.americanbankingnews.com - April 12 at 11:52 PM
	$1.33 Billion in Sales Expected for Zoetis Inc (ZTS) This Quarter www.americanbankingnews.com - April 12 at 2:40 AM
	Zoetis Stock Performance in 1Q18 finance.yahoo.com - April 10 at 4:14 PM
	Brokerages Expect Zoetis Inc (ZTS) Will Post Earnings of $0.69 Per Share www.americanbankingnews.com - April 10 at 3:18 PM
	Trade-War Olive Branch Fuels Rise By Stocks In 'Best Mutual Funds' finance.yahoo.com - April 10 at 10:03 AM
	Zoetis (ZTS) Rating Reiterated by Stifel Nicolaus www.americanbankingnews.com - April 9 at 4:40 PM
	Zoetis (ZTS) Upgraded to Strong-Buy by BidaskClub www.americanbankingnews.com - April 9 at 12:24 AM
	Zoetis (ZTS) Given Buy Rating at Stifel Nicolaus www.americanbankingnews.com - April 5 at 9:36 PM
	Zoetis (ZTS) Rating Reiterated by Cantor Fitzgerald www.americanbankingnews.com - April 5 at 7:26 PM
	May 25th Options Now Available For Zoetis (ZTS) www.nasdaq.com - April 5 at 4:15 PM
	Zoetis Inc (ZTS) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 5 at 3:36 PM
	Zoetis (ZTS) Price Target Raised to $89.00 www.americanbankingnews.com - April 5 at 12:56 PM
	BMO Capital Markets Analysts Give Zoetis (ZTS) a $65.00 Price Target www.americanbankingnews.com - April 5 at 12:39 PM
	BidaskClub Downgrades Zoetis (ZTS) to Hold www.americanbankingnews.com - April 4 at 11:26 PM
	Zoetis (ZTS) Upgraded by ValuEngine to "Buy" www.americanbankingnews.com - April 2 at 10:26 PM
	Zoetis (ZTS) Given a $75.00 Price Target at Cantor Fitzgerald www.americanbankingnews.com - April 2 at 8:40 PM
	Zoetis (ZTS) Downgraded to Sell at BidaskClub www.americanbankingnews.com - April 2 at 5:52 PM
	Zoetis (ZTS) Receives "Buy" Rating from Craig Hallum www.americanbankingnews.com - March 31 at 12:16 PM
	Cantor Fitzgerald Analysts Give Zoetis (ZTS) a $85.00 Price Target www.americanbankingnews.com - March 31 at 12:16 PM
	Zoetis (ZTS) Upgraded by Citigroup to Buy www.americanbankingnews.com - March 30 at 5:08 PM
	Buy Align Technology And Zoetis - Cramer's Lightning Round (3/28/18) seekingalpha.com - March 29 at 10:12 AM
	Zoetis to Host Webcast and Conference Call on First Quarter 2018 Financial Results finance.yahoo.com - March 29 at 10:12 AM
	Cantor Fitzgerald Reiterates $85.00 Price Target for Zoetis (ZTS) www.americanbankingnews.com - March 28 at 7:06 PM
	The Leaders Stagger: Cramer's 'Mad Money' Recap (Tuesday 3/27/18) www.thestreet.com - March 28 at 9:48 AM
	Zoetis Is Expanding Healthcare Products for Pets, Livestock finance.yahoo.com - March 28 at 9:48 AM
	Zoetis (ZTS) Given "Buy" Rating at Piper Jaffray www.americanbankingnews.com - March 27 at 12:34 PM
	Zoetis Inc (ZTS) Expected to Post Quarterly Sales of $1.33 Billion www.americanbankingnews.com - March 26 at 4:54 AM
	Critical Comparison: Zoetis (ZTS) & Acer Therapeutics (ACER) www.americanbankingnews.com - March 25 at 11:15 PM
	Brokerages Anticipate Zoetis Inc (ZTS) to Announce $0.69 Earnings Per Share www.americanbankingnews.com - March 24 at 5:20 PM
	Critical Comparison: Zoetis (ZTS) & Cara Therapeutics (CARA) www.americanbankingnews.com - March 21 at 11:10 PM
	Morgan Stanley Downgrades Zoetis Inc. (ZTS) to Equalweight - StreetInsider.com www.streetinsider.com - March 20 at 4:22 PM
	Zoetis Inc (ZTS) Insider Heidi C. Chen Sells 7,383 Shares www.americanbankingnews.com - March 19 at 7:28 PM
	Zoetis (ZTS) Rating Lowered to Equal Weight at Morgan Stanley www.americanbankingnews.com - March 19 at 6:12 PM
	Zoetis Downgraded As Valuation Approaches Morgan Stanley's Price Target - Benzinga www.benzinga.com - March 19 at 4:21 PM

Zoetis (NYSE:ZTS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Zoetis (NYSE:ZTS) Income Statement, Balance Sheet and Cash Flow Statement

Zoetis (NYSE ZTS) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff